Clinical Trials
32 trialsA Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Jecho Biopharmaceuticals Co., Ltd.
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
BAF_FRontier-1
Eli Lilly and Company
FRONTIER
Miltenyi Biomedicine GmbH
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
University of Miami
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Arovella Therapeutics Ltd
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma
Phramongkutklao College of Medicine and Hospital
BaseCAR-01
University Hospital, Basel, Switzerland
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
A Study to Evaluate the Safety and Clinical Efficacy of STR-P004
Starna Therapeutics
CAR-TIGUE
Assistance Publique - Hôpitaux de Paris
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Stanford University
G-CSF in NHL
Department of Medical Services Ministry of Public Health of Thailand
CLIO
IRCCS Azienda Ospedaliero-Universitaria di Bologna
An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
Sun Yat-sen University
A Real-World Study on Extranodal Lymphoma
Ruijin Hospital
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Bnai Zion Medical Center
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Sinocelltech Ltd.
CARTD-BG-1
Fundacion Clinic per a la Recerca Biomédica
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Ruijin Hospital
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Sociedad de Lucha Contra el Cáncer del Ecuador
Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation
Chang Gung Memorial Hospital
MIMOSA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
The First People's Hospital of Changzhou